Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”

Detalles Bibliográficos
Autor principal: Wambier, Carlos Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779256/
https://www.ncbi.nlm.nih.gov/pubmed/33408021
http://dx.doi.org/10.1016/j.ijantimicag.2020.106175
_version_ 1783631295385960448
author Wambier, Carlos Gustavo
author_facet Wambier, Carlos Gustavo
author_sort Wambier, Carlos Gustavo
collection PubMed
description
format Online
Article
Text
id pubmed-7779256
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-77792562021-01-04 Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” Wambier, Carlos Gustavo Int J Antimicrob Agents Letter to the Editor Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021-01 2021-01-04 /pmc/articles/PMC7779256/ /pubmed/33408021 http://dx.doi.org/10.1016/j.ijantimicag.2020.106175 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Wambier, Carlos Gustavo
Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
title Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
title_full Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
title_fullStr Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
title_full_unstemmed Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
title_short Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
title_sort focus on clinical outcomes of “hydroxychloroquine and azithromycin as a treatment of covid-19: results of an open-label non-randomized clinical trial”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779256/
https://www.ncbi.nlm.nih.gov/pubmed/33408021
http://dx.doi.org/10.1016/j.ijantimicag.2020.106175
work_keys_str_mv AT wambiercarlosgustavo focusonclinicaloutcomesofhydroxychloroquineandazithromycinasatreatmentofcovid19resultsofanopenlabelnonrandomizedclinicaltrial

Ejemplares similares